Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial

American Heart Journal

Volumn 166, Issue 3, 2013, Pages 442-448

  Kirchhof, Paulus ^a,b,c   Breithardt, Günter ^b,c   Camm, A John ^d   Crijns, Harry J ^e   Kuck, Karl Heinz ^c,f   Vardas, Panos ^g   Wegscheider, Karl ^c,h  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g UNIVERSITY OF CRETE   (Greece)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DRONEDARONE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COGNITION; CONTROLLED STUDY; DEATH; EARLY INTERVENTION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK; SCORING SYSTEM; SINUS RHYTHM; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE; HUMANS; LENGTH OF STAY; MALE; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 84883813982     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.05.015     Document Type: Article

References (48)

1. E.J. Benjamin, P.A. Wolf, and R.B. D'Agostino Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 10 1998 946 952
2. S. Stewart, C.L. Hart, and D.J. Hole A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 5 2002 359 364
3. L. Friberg, N. Hammar, and H. Pettersson Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF) Eur Heart J 28 19 2007 2346 2353
4. U. Stenestrand, J. Lindback, and L. Wallentin Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) Circulation 112 21 2005 3225 3231
5. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
6. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
7. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
8. S. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
9. I.C. Van Gelder, H.F. Groenveld, and H.J. Crijns Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 15 2010 1363 1373
10. P. Kirchhof, D. Andresen, and R. Bosch Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial Lancet 380 9838 2012 238 246
11. D. Roy, M. Talajic, and S. Nattel Rhythm control versus rate control for atrial fibrillation and heart failure N Engl J Med 358 25 2008 2667 2677
12. H. Calkins, K.H. Kuck, and R. Cappato 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society Heart Rhythm 9 4 2012 632 696e21
13. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation* Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 21 2012 2719 2747
14. D.J. Wilber, C. Pappone, and P. Neuzil Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial JAMA 303 4 2010 333 340
15. H. Calkins, M.R. Reynolds, and P. Spector Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses Circ Arrhythm Electrophysiol 2 4 2009 349 361
16. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 10 2011 e269 e367
17. A.C. Skanes, J.S. Healey, and J.A. Cairns Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2 2012 125 136
18. P. Kirchhof, A.B. Curtis, and A.C. Skanes Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society Eur Heart J 2013 published on line 23 January
19. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 9526 2006 1903 1912
20. M.G. Bousser, J. Bouthier, and H.R. Buller Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial Lancet 371 9609 2008 315 321
21. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 9397 2003 1691 1698
22. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 6 2005 690 698
23. D.G. Wyse, A.L. Waldo, and J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 23 2002 1825 1833
24. L. Kober, C. Torp-Pedersen, and J.J. McMurray Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 358 25 2008 2678 2687
25. S.H. Hohnloser, H.J. Crijns, and M. van Eickels Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 7 2009 668 678
26. B.N. Singh, S.J. Connolly, and H.J. Crijns Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter N Engl J Med 357 10 2007 987 999
27. T. Fetsch, P. Bauer, and R. Engberding Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial Eur Heart J 25 16 2004 1385 1394
28. S.J. Connolly, A.J. Camm, and J.L. Halperin Dronedarone in high-risk permanent atrial fibrillation N Engl J Med 365 24 2011 2268 2276
29. I. Van Gelder, V.E. Hagens, and H.A. Bosker A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
30. B.N. Singh, S.N. Singh, and D.J. Reda Amiodarone versus sotalol for atrial fibrillation N Engl J Med 352 18 2005 1861 1872
31. M. Patten, R. Maas, and P. Bauer Suppression of paroxysmal atrial tachyarrhythmias - results of the SOPAT trial Eur Heart J 25 16 2004 1395 1404
32. AFFIRM Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
33. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 9244 2000 1789 1794
34. J. Carlsson, S. Miketic, and J. Windeler Randomzied trial of rate-control versus rhythm-control in persistent atrial fibrillation J Am Coll Cardiol 41 2003 1690 1696
35. G. Opolski, A. Torbicki, and D.A. Kosior Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2 2004 476 486
36. L. Testa, G.G. Biondi-Zoccai, and A. Dello Russo Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis Eur Heart J 26 19 2005 2000 2006
37. J.S. Steinberg, A. Sadaniantz, and J. Kron Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Circulation 109 16 2004 1973 1980
38. P. Kirchhof, G.Y. Lip, and I.C. Van Gelder Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference Thromb Haemost 106 6 2011 1012 1019
39. S.J. Connolly, H.J. Crijns, and C. Torp-Pedersen Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter Circulation 120 13 2009 1174 1180
40. M.A. Tsadok, C.A. Jackevicius, and V. Essebag Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation Circulation 126 23 2012 2680 2687
41. R. Ionescu-Ittu, M. Abrahamowicz, and C.A. Jackevicius Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation rhythm vs rate control drug treatment Arch Intern Med 172 13 2012 997 1004
42. P. Kirchhof, J. Bax, and C. Blomstrom-Lundquist Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF' Eur Heart J 30 24 2009 2969c 2977c
43. U. Schotten, S. Verheule, and P. Kirchhof Pathophysiological mechanisms of atrial fibrillation: a translational appraisal Physiol Rev 91 1 2011 265 325
44. M.C. Wijffels, C.J. Kirchhof, and R. Dorland Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 7 1995 1954 1968
45. N. Voigt, N. Li, and Q. Wang Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation Circulation 125 17 2012 2059 2070
46. K. Kumagai, H. Nakashima, and H. Urata Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J Am Coll Cardiol 41 12 2003 2197 2204
47. P. Kirchhof Can we improve outcomes in AF patients by early therapy? BMC Med 7 2009 72
48. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 19 2010 2369 2429